Inflammatory bowel disease

The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies...

This study identifies a specific immune cell (γδ intraepithelial lymphocytes) that may fail before Crohn’s disease appears, which could help researchers develop early biomarkers or new therapies to prevent inflammation.

Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

Cure8 found this source from medindia.net, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.

This FDA approval adds another biologic option (an IL-23 inhibitor) for adults with moderate-to-severe Crohn’s disease, including both self-administered subcutaneous dosing and an IV induction route. New options may...

Regulators asked Roche to provide early-phase Crohn’s disease data before advancing review of a Phase 3 protocol for RO7790121, a monoclonal antibody targeting TL1A—an emerging target in IBD.

Research that maps neutrophil behavior in children with Crohn’s could reveal biological mechanisms and biomarkers relevant to disease progression or treatment response. Understanding neutrophil roles helps scientists...

Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

Cure8 found this source from science.org, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

Cure8 could only read part of this source from endpts.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.

Cure8 could only read part of this source from managedhealthcareexecutive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

This is a new FDA approval of an IL-23 inhibitor (guselkumab) for adults with moderately to severely active Crohn disease, adding another biologic treatment option. It’s notable because guselkumab offers both IV and...

This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...

A newly FDA-approved option (Tremfya/guselkumab) may offer more flexible dosing that could affect how people with moderate-to-severe Crohn’s start biologic treatment.

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

Cure8 could only read part of this source from zacks.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.

An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did...

A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...

An FDA approval means a new biologic option (guselkumab/Tremfya) is available for adults with moderately to severely active Crohn’s disease and may change prescribing choices. The approval highlights a dosing flexibility...

A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have...

An FDA approval means a new, approved IL‑23 inhibitor option (guselkumab/TREMFYA) is available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices and offering a fully...

An FDA approval means TREMFYA is now an additional, officially authorized treatment option for adults with moderately to severely active Crohn's disease. The drug offers both IV and SC induction choices and established...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.

Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.

Unintentional weight loss and malnutrition are common in Crohn’s and can affect energy, healing, and treatment. Practical diet and monitoring steps can help manage weight and nutrition. Working with your healthcare team...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Community and awareness. The original article is from msn.com.

Cure8 could only read part of this source from nexstar.tv, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and awareness.

Reducing long-term corticosteroid use matters because steroids have significant side effects when used repeatedly or chronically. The study suggests ileocaecal resection may lower steroid exposure for many patients, but...

Cure8 found this source from phl17.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and awareness. Open the original article for the full...

Based on the title and source metadata, this appears to be an event or fundraiser related to Inflammatory bowel disease, Crohn's disease, and Community and awareness. The original article is from msn.com.

Cure8 found this source from rollingout.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Symptoms and flares. Open the original article for the full...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Diet and lifestyle. The original article is from msn.com.

Stomach cramps are a common and often painful part of Crohn’s disease that can signal active inflammation or complications. Understanding causes and management options helps people with Crohn’s recognize when to seek...

Based on the title and source metadata, this appears to be a clinical trial phase 1 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

New treatment studies and biosimilars could affect future options and access to care. The piece also points out growing pediatric Crohn’s care and supports available (like an infusion center).

Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mental health and quality of life. Open the original article for...

This study suggests intestinal ultrasound findings early after diagnosis — especially achieving “transmural remission” within 3 months — may predict better 1-year outcomes (sustained steroid-free remission and less need...

Denied or cut-off long-term disability benefits can create immediate financial stress for people with Crohn’s disease who cannot work. Knowing how to document your medical limitations and when to seek legal help can...

Disability benefits can help people with moderate-to-severe Crohn’s cover lost income and higher medical costs. The SSA has specific IBD-related criteria and medical examples that can support a claim, so understanding...

Based on the title and source metadata, this appears to be a video related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from webmd.com.

The paper links a Crohn’s disease GWAS signal to reduced LACC1 expression in lymphocytes and to altered immunometabolic function, clarifying a potential mechanism by which genetic variation contributes to IBD risk. It...

Cure8 found this source from precisionmedicineonline.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker. Open the original article for the full...